NYSE$MTNB
Matinas BioPharma Holdings Inc · Q1 2025 earnings
Q1 2025 earnings · · After market close · Investor relations
Briefing
Matinas BioPharma reported Q1 2025 a net loss of $1.7M, diluted EPS of $-0.33.
For Q1 2025, Matinas BioPharma reported net loss was $1.7M, diluted EPS was $-0.33. The quarterly filing discusses operating priorities, liquidity, and sector-specific risks in MD&A.
- Net loss $1.7M.
- Diluted EPS $-0.33.
- MD&A highlights cash runway, pipeline progress, and macro risks.
Headline financials
Revenue & EPS history
Matinas BioPharma · Revenue · Quarterly
$0
Forward guidance
Outlook emphasizes clinical milestones, cash runway, and operating expense discipline.
Tailwinds
- Pipeline progress and partnership optionality.
- Cost controls and balance-sheet flexibility.
Headwinds
- Operating losses until commercialization.
- Trial timing and regulatory uncertainty.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2025
-2.1%
Avg return
Earnings day
-2.9%
Avg return
5 days after
-1.9%
Avg return
30 days after
37%
14 / 38 earnings
Positive
+43.0%
Q2 2025
Best reaction
-41.3%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | +2.6% | +4.3% | -32.2% | |
| Q2 2025 | +43.0% | +5.5% | +10.9% | |
| Q2 2024 | -1.3% | +9.0% | +17.3% | |
| Q1 2025 | +6.3% | +2.5% | +15.0% | |
| Q4 2025 | -6.0% | -7.5% | +21.2% | |
| Q3 2024 | -15.0% | -18.1% | -23.9% | |
| Q1 2024 | -1.1% | -1.1% | -10.7% | |
| Q4 2023 | -5.2% | +29.4% | -37.4% | |
| Q3 2023 | -24.3% | -31.9% | -21.9% | |
| Q2 2023 | -41.3% | -50.0% | -50.9% | |
| Q1 2023 | -12.5% | -15.5% | -26.0% | |
| Q4 2022 | +2.1% | -11.1% | -2.2% | |
| Q3 2022 | -3.3% | -5.0% | -15.2% | |
| Q2 2022 | -4.7% | -8.4% | -12.9% | |
| Q1 2022 | +6.7% | +6.5% | +32.0% | |
| Q4 2021 | +12.9% | +6.9% | +40.0% | |
| Q3 2021 | -6.8% | -2.8% | +3.7% | |
| Q2 2021 | -2.5% | -5.7% | +2.7% | |
| Q1 2021 | +2.6% | -3.8% | +7.1% | |
| Q4 2020 | -2.7% | -1.8% | -98.3% | |
| Q3 2020 | -2.6% | -3.6% | +29.0% | |
| Q2 2020 | -3.8% | -7.2% | -22.0% | |
| Q1 2020 | +8.9% | +11.7% | +29.7% | |
| Q4 2019 | -14.6% | -34.0% | -49.1% | |
| Q3 2019 | -4.8% | +31.2% | +96.8% | |
| Q2 2019 | +6.2% | +6.7% | +2.1% | |
| Q1 2019 | +1.8% | +10.0% | -7.8% | |
| Q4 2018 | -0.9% | -1.8% | -7.2% | |
| Q3 2018 | -25.2% | -29.8% | -28.8% | |
| Q2 2018 | -1.4% | +5.0% | +26.1% | |
| Q1 2018 | -1.0% | +0.6% | +8.6% | |
| Q4 2017 | -5.5% | -12.8% | -38.8% | |
| Q3 2017 | +2.6% | +4.4% | +24.6% | |
| Q2 2017 | +14.4% | +5.6% | +9.6% | |
| Q1 2017 | +2.9% | +7.6% | -7.3% | |
| Q3 2016 | -6.3% | -4.0% | -20.0% | |
| Q2 2016 | +3.2% | +1.5% | +64.7% | |
| Q1 2016 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q3 2014 | -3.3% | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro